Asked by: Jonathan Davies (Labour - Mid Derbyshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of (a) reviewing and (b) increasing the level of payment provided under the Vaccine Damage Payment Scheme.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
I would like to reiterate my deepest sympathies to all those individuals who have experienced harm following vaccination, and to their families.
I recognise many of the concerns that campaigners have raised regarding the Vaccine Damage Payment Scheme (VDPS). Their input will shape our ongoing consideration of reforms to the scheme.
In parallel, the Department continues to work with the NHS Business Services Authority, the administrators of the VDPS, to take further steps to improve the scheme, including through processing claims at a faster rate.
I will keep Parliament updated, as appropriate.
Asked by: Jonathan Davies (Labour - Mid Derbyshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the effectiveness of the Vaccine Damage Payment Scheme.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
I would like to reiterate my deepest sympathies to all those individuals who have experienced harm following vaccination, and to their families.
I recognise many of the concerns that campaigners have raised regarding the Vaccine Damage Payment Scheme (VDPS). Their input will shape our ongoing consideration of reforms to the scheme.
In parallel, the Department continues to work with the NHS Business Services Authority, the administrators of the VDPS, to take further steps to improve the scheme, including through processing claims at a faster rate.
I will keep Parliament updated, as appropriate.
Asked by: Jonathan Davies (Labour - Mid Derbyshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what plans he has to improve access to Padcev for (a) patients who have undergone chemotherapy and (b) all patients.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) makes recommendations for the National Health Service in England on whether new licensed medicines should be routinely funded for eligible patients based on an assessment of the evidence of clinical and cost effectiveness.
NICE issued guidance that recommends enfortumab vedotin (Padcev) with pembrolizumab (Keytruda), within its marketing authorisation, as an option for untreated unresectable or metastatic urothelial cancer in adults when platinum-based chemotherapy is suitable. It is now available for NHS patients in line with NICE’s recommendations. The guidance is available at the following link:
https://www.nice.org.uk/guidance/ta1097/chapter/1-Recommendation
NICE was unable to make recommendations on the use of Padcev in the treatment of people who have previously undergone chemotherapy as the manufacturing company, Astellas, did not provide an evidence submission. Astellas has confirmed that there is unlikely to be enough evidence that the technology is a cost-effective use of NHS resources in this population. NICE will review the position if the company decides that it wants to make an evidence submission.
Asked by: Jonathan Davies (Labour - Mid Derbyshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department plans to continue supporting the implementation of NHS England’s acute aortic dissection toolkit after the proposed abolition of NHS England.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department will continue to support the implementation of NHS England’s acute aortic dissection toolkit.
In 2022, NHS England published the Acute Aortic Dissection Toolkit to support service transformation across England. Initial implementation support was provided by NHS England’s national team, however, responsibility for implementation has now transitioned to regional commissioning teams and integrated care boards, to oversee and monitor progress. The toolkit includes self-assessment questionnaires for providers and clinical networks to use as part of their assurance and monitoring processes. In collaboration with the EARNEST trial, NHS England will undertake a stocktake of implementation progress across centres, the findings of which will be shared with regional commissioning teams and clinical networks to support any follow up actions as required.
NHS England’s national team is now working with the vascular and cardiac professional societies to develop a type B, elective aortic dissection toolkit, which is anticipated for publication in 2026.
Asked by: Jonathan Davies (Labour - Mid Derbyshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he plans to support the continued (a) development and (b) implementation of NHS England’s elective toolkit given NHS England's planned abolition.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The NHS England Elective toolkit does not have one single function, as there are multiple different toolkits available. For example, the Children and young people’s elective recovery toolkit and the Getting It Right First Time toolkit, to support the development of elective surgical hubs.
As part of the transformation programme, we are reviewing the appropriate options to merge existing functions between NHS England and the Department, to ensure we maintain progress on tackling the elective waiting list. We will continue to support the wider system through the transformation and will ensure they have the tools and resources available to deliver on the commitments outlined by the Government.
Cutting elective care waiting lists is a key priority for the Government, and the steps we have taken have resulted in a 220,000 reduction in the waiting list over the last year.
We have now exceeded our pledge to deliver an extra two million operations, scans, and appointments, having now delivered 5.2 million more appointments. This marks a vital first step to delivering on the commitment that 92% of patients will wait no longer than 18 weeks from referral to consultant-led treatment, in line with the National Health Service constitutional standard, by March 2029. We will create an NHS fit for the future, modernising care so that it takes place efficiently and closer to home, prioritising patient experience and ensuring that wherever you live in England, you will be seen, diagnosed, and treated in a timely way.
Asked by: Jonathan Davies (Labour - Mid Derbyshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what the planned timescale is for the abolition of Healthwatch England.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The closure of Healthwatch England and the transfer of its functions will require primary legislation. The Dash review of patient safety across the health and care landscape, published in July 2025, recommends that the strategic functions of Healthwatch England are transferred into the new patient experience directorate of the Department. The timing of this is subject to the will of Parliament, and will happen when parliamentary time allows.
Asked by: Jonathan Davies (Labour - Mid Derbyshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department plans to maintain the collective patient voice function supported by Healthwatch England in the reformed NHS structures.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Dr Dash’s review of patient safety across the health and care landscape was published in July 2025. It recommended that the strategic functions of Healthwatch England are transferred into the new patient experience directorate of the Department. This new directorate will be responsible for overseeing the collection of more informed feedback from both patients and carers and significantly improving the complaints function across the National Health Service. It ensures that the NHS properly manages and learns from complaints.
The abolition of Healthwatch England, the transfer of its functions, and the changes to local Healthwatch will require primary legislation. The timing of this is subject to the will of Parliament and will happen when parliamentary time allows.
Asked by: Jonathan Davies (Labour - Mid Derbyshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he has made an assessment with Cabinet colleagues of the potential merits of treating post traumatic stress disorder in veterans with (a) medical cannabis and (b) MDMA assisted therapy.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
We recognise that the use of cannabis-based medicines and psychedelic-assisted psychotherapies, such as MDMA to treat mental illness, is gaining attention both within the medical and scientific communities as well as within the public more broadly. The licensing regime for controlled drugs allows legitimate medical research to take place with an appropriate licence and safeguards. A number of clinical studies are already being conducted, although no such substance has yet been licensed as safe and effective in the treatment of mental health conditions.
The Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Research supports the safe and scientifically sound conduct of clinical trials in this area and provides regulatory and scientific advice to companies at all stages of developing medicines. Any application for a marketing authorisation, otherwise known as a product licence, will be determined by the MHRA.
In line with the development of all medicines, as the evidence base grows and medicinal products are licensed, we will make sure that they are made available to patients, including through the National Health Service, if they are recommended by the National Institute of Health and Care Excellence.
Asked by: Jonathan Davies (Labour - Mid Derbyshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to (a) support people living with long covid, (b) retain the services provided by the long covid clinic and (c) develop systems of treatment and diagnosis to identify long covid.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
NHS England has invested £314 million since the start of the pandemic to provide care and support for people with long COVID. This includes establishing specialist clinics throughout England to assess adults, children, and young people who are experiencing the long-term effects of COVID-19 infection. A further £86.7 million of funding was included in integrated care board (ICB) core allocations for 2024/25, and specific regional funding was also allocated for assurance and system support.
These services offer physical, cognitive, and psychological assessment, and, where appropriate, refer patients onto existing services for treatment and rehabilitation. More information can be found via the NHS website at the following link:
https://www.england.nhs.uk/coronavirus/post-covid-syndrome-long-covid/
The commissioning and service provision of long COVID services are the responsibility of local ICBs, which are allocated funding by NHS England to meet local needs and priorities and to improve outcomes.
Between 2019/20 and 2023/24, through the National Institute for Health and Care Research and the Medical Research Council, we have invested over £57 million on research into long COVID, with almost £40 million of this through two specific research calls on long COVID. The funded projects aim to improve our understanding of the diagnosis and underlying mechanisms of the disease and the effectiveness of both pharmacological and non-pharmacological therapies and interventions, as well as to evaluate the effectiveness of clinical care.
Asked by: Jonathan Davies (Labour - Mid Derbyshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department has had discussions with the University of Derby on the development of the drug Remdesivir for the treatment of long Covid.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
We are aware of the University of Derby’s study looking at the use of the drug Remdesivir for the treatment of long COVID, however officials have not discussed the study with the research team. The study is being managed by the University of Plymouth’s Peninsula Clinical Trials Unit. Since 2008, the Department, through the National Institute for Health and Care Research, has funded clinical trials units in England to support developments in the design and delivery of efficient and innovative research. We will follow the progress of the study to understand the implications for policy and practice.